Global Advice Network | Borgergade 111 | DK - 1300 Copenhagen K
E-Mail: info@business-anti-corruption.org | Phone: (+45) 60 88 10 44

Healthcare Corruption Risks in Approvals and Hospital Procurement

Medical device approvals and hospital procurement sit at two powerful points where commercial influence can become corruption. A manufacturer may distort clinical evidence or cultivate regulatory contacts to secure market access, while a supplier may manipulate specifications, tender scoring or invoicing to win public contracts. The resulting harms extend beyond balance-sheet loss: unsafe devices, inflated costs and compromised care can follow corrupted decisions into hospitals.

For Australian organisations, these risks cross the TGA, state and territory health procurement, distributors and importers. Exposure can arise through an overseas regulator, an agent, a local supplier or a corrupted tender record. Effective control follows the full chain from evidence generation and registration to purchase, delivery, maintenance and renewal, rather than treating compliance as a final approval step.

Where Corruption Enters the Healthcare Chain

Before a device reaches a clinician, sponsors and manufacturers assemble technical dossiers, appoint local agents, fund studies and engage regulatory advisers. Weak oversight can allow fabricated data, undisclosed conflicts or paid experts to influence an approval decision without producing a clinically meaningful product. The danger is not limited to an outright fake; selective reporting of faults, concealed change requests and unrepresentative testing can make risk look smaller than it is.

Procurement creates a second pressure point. Clinical preferences, budget cycles, emergency purchases and clinician-supplier relationships can affect which products are specified and accepted. A hospital may pay above market for a familiar brand, accept a maintenance promise that does not materialise, or keep buying a product because the supplier controls software and consumables. Each decision creates an opportunity for kickbacks, ghost invoicing and conflicts hidden behind commercial confidentiality.

Corruption and extortion are related but distinct threats, so teams need different escalation paths. The bribery and extortion distinction is useful here: a bribe seeks a benefit through improper influence, while extortion uses coercion or fear. A distributor threatened with losing a contract and a distributor offered a payment to manipulate tender outcomes may look similar in invoices, yet they require different legal analysis, evidence preservation and response.

Regulatory Capture and Approval Integrity

Regulatory capture develops when formal authority is influenced by private wealth, networks or dependence on a narrow group of expertise. Sponsor-submitted evidence may receive little challenge, advisers may move quickly between companies and assessment bodies, and regulators may face pressure to attract investment or avoid reputational damage. The result can be expedited access, favourable conditions for a product or delayed action against weak evidence.

Approval staff also face internal risks, including manipulated conflict-of-interest declarations, confidential material leaking to bidders, and changes to review priorities. In some markets, a politically connected distributor can become the practical gatekeeper even when law formally places approval with a government agency. Indicators include repeated exceptional treatment, unusual sponsor influence over meeting agendas, unexplained technical advice and inconsistent enforcement for equivalent products.

Integrity depends on traceable decisions and independent challenge. Major scientific conclusions should be reviewed outside the sponsor’s chain, conflicts disclosed, and departures from assessment criteria documented. Regulators need mechanisms for whistleblowing, random post-market checks and transparent correction of earlier decisions. Companies can reinforce these systems by keeping approval correspondence, study commitments and consultant instructions in one defensible record.

Hospital Tendering and Conflicted Decisions

Hospital tenders compress many judgement calls into a short process. A specification drafted around one supplier, confidential prices shared before close, an evaluator with a family or financial connection, and a change to scoring criteria after bids open are classic warning signs. Corruption may also occur after award, through inflated variations, unnecessary accessories, phantom services or extensions that avoid a fresh competitive process.

Australian public hospitals operate through state procurement frameworks and platforms such as AusTender, with panels and prequalification schemes used by health departments in New South Wales and Queensland. Large hospital networks in Sydney and Melbourne also buy through approved supplier arrangements. These structures create legitimate routes for small Australian device firms and distributors, yet complex panels can obscure who set specifications, received rebates and approved substitutions.

International expansion adds another layer. A supplier entering India, for example, may encounter state-level approvals, distributor exclusivity and hospital committees operating under different rules. A country-level resource such as the India country snapshot should be combined with local legal advice and agent verification before contracts are signed. The key questions concern ownership, referral payments, site access and whether commission is calculated from legitimate sales performance rather than an improper approval.

Mispricing, Hidden Value and Diversion

Mispricing in healthcare often hides inside apparently ordinary commercial terms. Equipment may be invoiced above its market value, discounts may be used to conceal rebates, or free devices may be tied to multi-year consumables at excessive prices. Maintenance contracts can include visits that never occur, software licences that are duplicated and training sessions delivered to a handful of staff. A fraud examiner should test the total cost of ownership, not merely the price printed on the purchase order.

Valuation expertise can itself be manipulated. Lessons from the art and antiquities market show how false valuation methods can give a questionable asset the appearance of legitimacy and move value across borders. Medical-device schemes can use a parallel logic by overstating the value of intellectual property, donated equipment or second-hand devices. The relevant controls are independent benchmarking, evidence of fair transfer values and confirmation that the asset or discount actually reached the intended buyer.

Asset diversion can compound the problem. Devices imported for a public hospital programme may be sold through a related supplier while invoices record fictitious deliveries. Counterfeit or nonconforming components can enter under genuine documentation, creating patient safety risks procurement staff may never see. Clinical inventory controls, serial-number reconciliation and post-delivery sampling are therefore part of anti-corruption work, not merely stock management.

Australia’s Regulatory and Procurement Environment

Australia’s medical-device regulator, the Therapeutic Goods Administration, is based in Canberra. Manufacturers and sponsors seeking inclusion in the Australian Register of Therapeutic Goods deal with Australian listing and conformity-assessment requirements, post-market obligations and public regulatory information through AusPAR. Australia’s relatively transparent regulator still depends on sponsors to provide complete data, so a device may satisfy formal registration requirements while commercial pressure distorts the evidence behind it.

Hospital purchasing is distributed across public health services, private hospitals and approved suppliers. Procurement hubs in Sydney and Melbourne coordinate sizeable contracts, while AusTender and state panels influence how public money is committed. Australian supply chains include local distributors, service technicians and small specialist manufacturers whose market access depends on fair tender rules. Concealed side payments and conflicts are especially damaging to confidence in this local market.

Imports create a further Australian checkpoint. Customs declarations, biosecurity controls and product documentation can reveal mismatched descriptions, unapproved consignments or duplicate serial numbers, while local sponsors remain responsible for device quality supplied here. The foreign bribery provisions of the Corporations Act 2001 and falsity provisions of the Crime Act 1901 can reach conduct designed to influence overseas public decisions, including improper payments through an intermediary. A defensible trail links each imported device to its approval, tender and end user.

Cross-Border Channels That Conceal Risk

Cross-border distribution magnifies opacity. An Australian manufacturer may sell through a master distributor, national partner, regional agent and freight consolidator, with each contract shifting risk and adding discretion. A useful red flag is a counterparty that cannot explain who owns goods at each stage, insists on cash settlement or resists disclosing commissions. Another is an invoice split just below a reporting threshold, a pattern that can conceal tax and corruption risk.

Third parties can also carry political influence, sanctioned ownership or diversion risk that does not appear in the signed contract. Due diligence should identify beneficial owners, verify bank accounts in the company’s name, test agents against an activity profile and check sanctions and export controls. Success fees tied to securing a government approval deserve particular scrutiny because they reward influence over value. Contracts should prohibit facilitation payments and require books, records and audit access.

Complex payment trails require the same disciplined reconciliation used in other high-value transactions. The recordkeeping challenges associated with casino jackpot flows offer a useful analogy: a large balance can appear legitimate while its underlying ledger is incomplete. Device sales can show similar opacity when rebates, credits and bundled fees are recorded separately. Matching contracts, goods-received notes, serial numbers, patient-use data and bank entries can expose a payment that has no corresponding commercial or clinical outcome.

Controls That Withstand Scrutiny

Controls should match every stage of the risk chain and identify who owns each decision. The most useful measures are specific enough to test, assignable to a role and linked to evidence an auditor can inspect. They also need a route for staff to report concerns without retaliation, particularly where commercial relationships are long-standing and valuable.

Essential Control Sets

Regulatory and counterparty due diligence

  • Screen agents, distributors and clinical consultants for ownership, sanctions, adverse media and conflicts that could distort approvals or tender advice.
  • Independently validate product claims, study reports, references and certificates against source records rather than accepting sponsor or vendor assurances.
  • Separate legitimate technical fees from success payments, and document the business reason for every commission or hospitality benefit.
  • Keep an approval file linking dossier changes, regulator correspondence, due diligence decisions and approved corrective actions.

Procurement and monitoring safeguards

  • Rotate or independently review sensitive tender roles, document scoring changes and require a beneficial-ownership declaration from bidders and advisers.
  • Test prices against independent benchmarks and compare the full package, including maintenance, consumables, software, training and expected useful life.
  • Reconcile invoices and credits with delivery evidence, serial numbers, service reports, hospital inventory and the general ledger before payment.
  • Monitor repeat exceptions, unusual variations, split invoices, related suppliers and adverse signals, then preserve evidence and escalate credible concerns.

The point to retain is that integrity in medical device approvals and hospital procurement cannot rest on a product’s regulated status, a hospital’s tender policy or a supplier’s reputation. It depends on independently verifiable evidence at every hand-off, from regulatory evidence and intermediary ownership to pricing, delivery and patient-use outcomes. Where those records align, confidence is earned; where they do not, the gap is where corruption can operate.

copyright © Global Advice Network